Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News on Pharma

This Cancer Treatment Stock Nears A Buy Point As Quarterly Results Loom

Zai Lab stock is in a cup-with-handle base before Q2 results due Thursday.

Investors Business Daily

Shares in European drug companies hit four-month low as Trump tariffs loom

President repeats threat to bring in levies ‘within next week or so’ in attempt to get companies to move production to US

The Guardian - UK

Fake Viagra is the UK’s most seized counterfeit drug - here's how to avoid it

Fake Viagra, real problems – the UK’s most seized counterfeit drug revealed

Evening Standard

From analysis to the latest developments in health,
read the most diverse news in one place.

Ozempic, Botox, Eliquis: How Tariffs on Europe Could Impact Drug Prices (And What To Do About It)

Most medications come from Europe. Does that mean the new tariffs on the EU will drive drug prices higher?

Kiplinger

Why S&P 500 Stock Amgen Stumbled Despite Its Beat-And-Raise Quarter

Amgen stock dropped Wednesday despite a strong second quarter as investors look ahead to the next weight-loss readouts.

Investors Business Daily

Inspire Medical Systems Crashes 32% As Eli Lilly's GLP-1 Weighs On Guidance

Inspire Medical Systems crashed Tuesday after the maker of implantable sleep apnea devices called out GLP-1 drugs for weighing on sales.

Investors Business Daily

Biogaran sale talks renew fears over foreign control of French pharma

France’s top generic drug maker, Biogaran, could soon be sold to a British investment fund, raising new fears about the country’s control over vital medicines.

Radio France Internationale

Read news from The Economist, FT, and more,
with one subscription

Syntex: How To Find & Own America's Greatest Opportunities

Syntex made a move of 450% in about six months and this drug stock was one of my best winners.

Investors Business Daily

Weight loss drugs could soon be used to treat these seven other health conditions

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some success

The Independent UK

Why Drugmaker Teva Pharmaceutical Narrowed Full-Year Guidance After Beating Q2 Earnings

Teva stock is trading below key levels.

Investors Business Daily

UnitedHealth Stock Drags on Dow: Stock Market Today

Corporate earnings have dominated Wall Street's attention this week, but that changes on Wednesday.

Kiplinger

Ministers take note: now is the moment to fight to keep AstraZeneca’s listing in London

One hopes cogs are turning in Westminster after Pascal Soriot’s affectionate talk of US at pharmaceutical giant’s half-year results

The Guardian - UK

US health officials crack down on kratom-related products after complaints from supplement industry

U.S. health officials are cracking down on an opioid-like ingredient being added to drinks, supplements and other products

The Independent UK

Novo Nordisk Cuts Earning Forecasts Again, Names New CEO

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, on Tuesday lowered its earning forecasts again as it unveiled a new chief executive to tackle "recent market challenges".

International Business Times

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

AstraZeneca chief executive hails ‘vital importance of US’ as Trump tariffs loom

Pascal Soriot refuses to be drawn, however, on reports AZ could move its main stock market listing across the Atlantic

Investors Business Daily

Merck Stock Falls After Layoff Announcement, Gardasil Sales Drop

Merck stock fell early Tuesday after Q2 results. The Dow Jones drugmaker plans for job cuts as part of restructuring initiative.

The Guardian - UK

Trump’s 15% tariff on medicines will harm patients, say EU drugmakers

Trade group says levy will reduce access, disrupt supply chains and cut R&D

Garmin-style energy tracking just arrived on a wearable that costs a fraction of a new Fenix

New BioCharge Energy feature brings real-time recovery insights to Amazfit’s affordable Helio Strap

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Sarepta will resume gene therapy shipments after FDA review of recent patient death

Shares of drugmaker Sarepta Therapeutics surged in afterhours trading Monday after the company said it would resume shipping its gene therapy

International Business Times

Ireland's 'Economic Miracle' At Risk From Tariffs

The deal between the United States and the European Union may have averted a transatlantic trade war, but worries persist in Ireland where crucial sectors are dependent on US multinationals.

The Independent UK

Weight-loss jab Wegovy sees another prescription boost after ban on copycats

Novo CEO ousted in May, in place until successor named

Investors Business Daily

Sarepta Therapeutics' Brutal Week Continues With Bad News Out Of Europe

Sarepta Therapeutics' brutal week continued Friday after European officials rejected the company's controversial gene therapy, Elevidys.

Investors Business Daily

The Hits Keep Coming For Sarepta. Why Its Latest Setback Creates A 'Dangerous Precedent.'

Sarepta stock plunged again Thursday on a report the FDA will require additional clinical testing to validate the safety profile of Elevidys.

Investors Business Daily

West Pharma Catapults, Making A Bullish Move, On Unexpectedly Strong Earnings

West Pharmaceutical stock catapulted Thursday after the medical player blew second-quarter expectations out of the water.

Investors Business Daily

Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work?

Insmed stock is soaring as it approaches the potential approval of its second drug. CEO Will Lewis calls it a "skeleton key."

1 … 5 6 7 8

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Investor Business Daily

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.